Pharma News

Around 19 Crore Indians Likely to Suffer from Skin Diseases by 2015 – notes Frost & Sullivan

(Business Wire India; 2nd May, 2014); The skin care segment has shown tremendous growth and emerged as a potential investment area for players in recent years. From treatment of common skin care diseases, the skin care industry has evolved to the age of cosmetic and anti-aging treatments. The overall skin care market is expected to grow with the rise in demand of various skin care services. Factors like global warming, anti-aging solutions, new product innovations, growing media influence, etc. are driving this market. Boosted by growing consumer demand, rise in disposable incomes, lifestyle related disorders, craze for cosmetic surgeries, obsession for young-looking skin, low cost of treatment, and booming medical tourism, the skin care market in India is likely to expand and emerge as a potential investment area for players.

ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia

(1st May, 2014); At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migraine. The first poster presentation, on April 28th, found that two hours after treatment with electroCore’s nVNS therapy patients who had both chronic migraine and medication overuse headache were pain free in 33% of attacks while significant pain relief (mild or no pain) was noted in 50% of attacks. In the second poster presented on May1st it was found that 45 % of patients, with migraine without aura, were pain free within 30 minutes of just one dose of nVNS therapy.

Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

(30th Apr, 2014);Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

Appointment of Dr. Arun Chandavarkar as CEO and Joint Managing Director at Biocon Ltd.

(28th Apr, 2014); Biocon Ltd., Asia's premier biotechnology company, announced that the Board of Directors of the Company, in their meeting on last thursday, have approved the induction of Dr. Arun Chandavarkar, on to the board of Biocon Limited. He has also been appointed as Chief Executive Officer and Joint Managing Director.

Pages